Academic Journal

Vipidia is a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

Bibliographic Details
Title: Vipidia is a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes
Authors: T. B. Morgunova, V. V. Fadeev
Source: Медицинский совет, Vol 0, Iss 2, Pp 66-69 (2015)
Publisher Information: Remedium Group LLC, 2015.
Publication Year: 2015
Collection: LCC:Medicine
Subject Terms: сахарный диабет, сахароснижающие препараты, гликемия, инкретин, глюкагоноподобный пептид-1, випидия, diabetes mellitus, hypoglycemic agents, glycemia, incretin, glucagon-like peptide-1, vipidia, Medicine
Description: The global number of patients with diabetes mellitus (DM) has been growing steadily. Over the past decade, the number has more than doubled and reached 371 million people by 2013. [1] In most cases it is type 2 diabetes. The dangerous consequences of DM include micro- and macrovascular complications: nephropathy, retinopathy, lesions of the major blood vessels in the heart, brain and lower limbs. Late complications of DM are a major cause of disability and mortality of the patients.
Document Type: article
File Description: electronic resource
Language: Russian
ISSN: 2079-701X
2658-5790
Relation: https://www.med-sovet.pro/jour/article/view/122; https://doaj.org/toc/2079-701X; https://doaj.org/toc/2658-5790
DOI: 10.21518/2079-701X-2015-2-66-69
Access URL: https://doaj.org/article/35b84b4da44e45aea203c9b7a59c5bcb
Accession Number: edsdoj.35b84b4da44e45aea203c9b7a59c5bcb
Database: Directory of Open Access Journals
Description
ISSN:2079701X
26585790
DOI:10.21518/2079-701X-2015-2-66-69